CORT logo

CORT
Corcept Therapeutics Inc

4,443
Mkt Cap
$3.92B
Volume
15.00
52W High
$117.33
52W Low
$28.66
PE Ratio
40.38
CORT Fundamentals
Price
$36.48
Prev Close
$35.34
Open
$35.40
50D MA
$51.21
Beta
1.28
Avg. Volume
2.69M
EPS (Annual)
$1.23
P/B
5.88
Rev/Employee
$1.35M
$5,341.86
Loading...
Loading...
News
all
press releases
JPMorgan Chase & Co. Increases Position in Corcept Therapeutics Incorporated $CORT
JPMorgan Chase & Co. raised its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 223.4% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst
The company guided for $900 million to $1 billion in 2026 revenue.
Stocktwits·5h ago
News Placeholder
Corcept Therapeutics Q4 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) reported higher revenue in 2025 and issued 2026 guidance as executives used the company's fourth-quarter earnings call to address two major setbacks: an adverse...
MarketBeat·8h ago
News Placeholder
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for...
Business Wire·9h ago
News Placeholder
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
Corcept (CORT) delivered earnings and revenue surprises of -24.53% and -20.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9h ago
News Placeholder
CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc.
CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc. CORT Stockholder Notice: Shareholder Rights Law Firm...
PR Newswire·14h ago
News Placeholder
Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.07 EPS
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) posted its earnings results on Tuesday. The biotechnology company reported $0.20 EPS for the quarter, missing analysts' consensus estimates of...
MarketBeat·14h ago
News Placeholder
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...
Business Wire·15h ago
News Placeholder
INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30...
Business Wire·19h ago
News Placeholder
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline Corcept Therapeutics (CORT) Litigation: Hagens...
PR Newswire·22h ago
<
1
2
...
>

Latest CORT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.